Abstract
Importance Type 2 diabetes mellitus (T2DM) and elevated glucose levels have been inversely associated with aortic aneurysms. However, the causality of this relationship remains uncertain. Additionally, there is a lack of studies investigating the association between glycemic traits and imaging-based thoracic aortic phenotypes.
Objective We investigated whether T2DM and glycemic measures (fasting glucose (FG), fasting insulin (FI), glycated hemoglobin (HbA1c), and 2-hour post-load glucose (2hPG)) are causally associated with various imaging and clinical thoracic aortic phenotypes.
Design, setting, and participants We performed Mendelian randomization (MR) analysis using summary statistics from genome-wide association studies of glycemic traits (GT) and aortic phenotypes. We employed a two-sample univariate MR (UVMR) followed by a multivariable MR and MR analysis using a cluster-based approach.
Main Outcomes and Measures The outcome includes imaging-based ascending and descending aortic diameters (AAoD and DAoD), aortic distensibility (AoDist) and strain (AoStr), and thoracic aortic aneurysm and dissection (TAAD). The GT include FI, FG, HbA1c, 2hPG and T2DM.
Results We observed an inverse association between 2hPG, FG, HbA1c, and T2DM and AAoD, DAoD. For instance, the genetically predicted increases levels of 2hPG, FG, HbA1c, and T2DM were associated with decreased AAoD (2hPG β= -0.2, p=3x10-08; FG β= -0.21, p=5x10-05; HbA1c β= -0.36, p=2x10-07; T2DM β=-0.04, p=2x10-04) and reduce risk TAAD (2hPG decreased TAAD (2hPG OR= 0.70, p=4x10-04; FG OR= 0.58, p=3x10-05; HbA1c OR= 0.62, p=5x10-03; T2DM OR= 0.90, p=6x10-6). Further investigation showed that the inverse association between T2DM and aortic phenotypes is driven by genetic predictors of T2DM beta cell proinsulin clusters. UVMR and Proteomic MR showed a strong association with aortic phenotypes for genes, such as AGER, GLRX, TCF7L2, and GCK, which are known to play an important role in glucose regulation.
Conclusion and relevance Our findings suggest a potentially causal impact of GT on the aortic vasculature. Furthermore, specific glucose regulation genes such as GCK, AGER, and TCF7L2 appear to contribute to this process, opening avenues for potentially leveraging the druggability of these genes for treatment or preventions of TAAD.
Competing Interest Statement
We thank the Type 2 Diabetes Global Genomics Initiative (T2DGGI) for generation of association summary statistics without UKBB and MVP; H.T. is supported by the Gates-Cambridge Trust and NIH Oxford-Cambridge scholars program;MGL was supported by the Doris Duke Foundation (Award 2023-0224) and US Department of Veterans Affairs Biomedical Research and Development Award IK2-BX006551, and has received research funding to the institution trial from Myome unrelated to this work. The content of this manuscript does not represent the views of the Department of Veterans Affairs or the United States Government; D.K. Is an employee at and has equity in Bitterroot Bio unrelated to the current research;
Funding Statement
CT received K01 award and AHA funding support
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used openly available before initiation of the study and original data sources are stated in the supplementary material of the manuscript with the accession number of publications with original data sources
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
